| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer
|
Osorio, J.C.
|
|
|
28 |
3 |
p. 583-589
|
artikel
|
| 2 |
A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors
|
Wagner, A.J.
|
|
|
28 |
3 |
p. 541-546
|
artikel
|
| 3 |
A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852)
|
Thaker, P.H.
|
|
|
28 |
3 |
p. 505-511
|
artikel
|
| 4 |
Biomarker-directed molecularly targeted therapy: the importance of prospective evaluation
|
Stinchcombe, T.E.
|
|
|
28 |
3 |
p. 453-454
|
artikel
|
| 5 |
Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study
|
Kelley, R.K.
|
|
|
28 |
3 |
p. 528-534
|
artikel
|
| 6 |
Cabozantinib: targeted therapy back to the future?
|
Abou-Alfa, G.
|
|
|
28 |
3 |
p. 450-451
|
artikel
|
| 7 |
Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials
|
Khosrow-Khavar, F.
|
|
|
28 |
3 |
p. 487-496
|
artikel
|
| 8 |
Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine
|
Batth, I.S.
|
|
|
28 |
3 |
p. 468-477
|
artikel
|
| 9 |
Different efficacy of ramucirumab in patients with metastatic gastric and gastroesophageal junction cancer according to ECOG performance status
|
Roviello, G.
|
|
|
28 |
3 |
p. 665-666
|
artikel
|
| 10 |
Differential gene expression profiling of matched primary renal cell carcinoma and metastases reveals upregulation of extracellular matrix genes
|
Ho, T.H.
|
|
|
28 |
3 |
p. 604-610
|
artikel
|
| 11 |
Does severe toxicity affect global quality of life in patients with metastatic colorectal cancer during palliative systemic treatment? A systematic review
|
Schuurhuizen, C.S.E.W.
|
|
|
28 |
3 |
p. 478-486
|
artikel
|
| 12 |
Drug-sensitiveFGFR3 mutations in lung adenocarcinoma
|
Chandrani, P.
|
|
|
28 |
3 |
p. 597-603
|
artikel
|
| 13 |
Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial
|
Loibl, S.
|
|
|
28 |
3 |
p. 497-504
|
artikel
|
| 14 |
Dual HER2 inhibition and pathological complete response in early breast cancer: increasing success of treatment by improving patient selection
|
Curigliano, G.
|
|
|
28 |
3 |
p. 441-443
|
artikel
|
| 15 |
3D waterfall plots: a better graphical representation of tumor response in oncology
|
Castanon Alvarez, E.
|
|
|
28 |
3 |
p. 454-456
|
artikel
|
| 16 |
Editorial board
|
|
|
|
28 |
3 |
p. ii-iii
|
artikel
|
| 17 |
Efficacy of androgen deprivation therapy and the role of oxidative stress
|
Price, D.K.
|
|
|
28 |
3 |
p. 451-453
|
artikel
|
| 18 |
Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram
|
Pietrantonio, F.
|
|
|
28 |
3 |
p. 555-561
|
artikel
|
| 19 |
Gene polymorphisms in antioxidant enzymes correlate with the efficacy of androgen-deprivation therapy for prostate cancer with implications of oxidative stress
|
Shiota, M.
|
|
|
28 |
3 |
p. 569-575
|
artikel
|
| 20 |
High incidence of interstitial lung disease following practical use of osimertinib in patients who had undergone immediate prior nivolumab therapy
|
Kotake, M.
|
|
|
28 |
3 |
p. 669-670
|
artikel
|
| 21 |
Impact of primary metastatic bone disease in germ cell tumors: results of an International Global Germ Cell Tumor Collaborative Group G3 Registry Study
|
Oing, C.
|
|
|
28 |
3 |
p. 576-582
|
artikel
|
| 22 |
Incidence of second tumors after treatment with or without radiation for rectal cancer
|
Rombouts, A.J.M.
|
|
|
28 |
3 |
p. 535-540
|
artikel
|
| 23 |
Industry corner: perspectives and controversies - The challenges of patient access to new medicines
|
Gann, C.-N.
|
|
|
28 |
3 |
p. 658-663
|
artikel
|
| 24 |
Integrating communication as a core skill in the global curriculum for medical oncology
|
Horlait, M.
|
|
|
28 |
3 |
p. 670-671
|
artikel
|
| 25 |
Interventions for preventing cardiomyopathy due to anthracyclines: a Bayesian network meta-analysis
|
Abdel-Qadir, H.
|
|
|
28 |
3 |
p. 628-633
|
artikel
|
| 26 |
Investigating the poor outcomes ofBRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials
|
Seligmann, J.F.
|
|
|
28 |
3 |
p. 562-568
|
artikel
|
| 27 |
Moving beyond sorafenib alone in advanced hepatocellular carcinoma: is hepatic arterial infusion chemotherapy the best option?
|
Fornaro, L.
|
|
|
28 |
3 |
p. 667
|
artikel
|
| 28 |
Multimodality treatment for esophageal adenocarcinoma: multi-center propensity-score matched study
|
Markar, S.R.
|
|
|
28 |
3 |
p. 519-527
|
artikel
|
| 29 |
MultiplexKRAS G12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction
|
Janku, F.
|
|
|
28 |
3 |
p. 642-650
|
artikel
|
| 30 |
Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC)
|
Mesnage, S.J.L.
|
|
|
28 |
3 |
p. 651-657
|
artikel
|
| 31 |
Network-guided modeling allows tumor-type independent prediction of sensitivity to all-trans-retinoic acid
|
Bolis, M.
|
|
|
28 |
3 |
p. 611-621
|
artikel
|
| 32 |
Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury
|
Gelsomino, F.
|
|
|
28 |
3 |
p. 671-672
|
artikel
|
| 33 |
PARP inhibitor and chemotherapy combination trials for the treatment of advanced malignancies: does a development pathway forward exist?
|
Matulonis, U.A.
|
|
|
28 |
3 |
p. 443-447
|
artikel
|
| 34 |
Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm
|
Haddox, C.L.
|
|
|
28 |
3 |
p. 673-675
|
artikel
|
| 35 |
Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer
|
Matulonis, U.A.
|
|
|
28 |
3 |
p. 512-518
|
artikel
|
| 36 |
Phase II study of cabazitaxel with or without abiraterone acetate and prednisone in patients with metastatic castrate resistant prostate cancer after prior docetaxel and abiraterone acetate
|
Kessler, E.R.
|
|
|
28 |
3 |
p. 668
|
artikel
|
| 37 |
Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial
|
Belin, L.
|
|
|
28 |
3 |
p. 590-596
|
artikel
|
| 38 |
Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition
|
Kim, S.T.
|
|
|
28 |
3 |
p. 547-554
|
artikel
|
| 39 |
Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance
|
Bonavida, B.
|
|
|
28 |
3 |
p. 457-467
|
artikel
|
| 40 |
Should rectal cancer located 10–15 cm from the anal verge be defined as colon cancer
|
Swets, M.
|
|
|
28 |
3 |
p. 664-665
|
artikel
|
| 41 |
Table of Contents
|
|
|
|
28 |
3 |
p. iv-vi
|
artikel
|
| 42 |
Treatment outcomes for older patients with relapsed/refractory aggressive lymphoma receiving salvage chemotherapy and autologous stem cell transplantation are similar to younger patients: a subgroup analysis from the phase III CCTG LY.12 trial
|
Davison, K.
|
|
|
28 |
3 |
p. 622-627
|
artikel
|
| 43 |
Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study
|
McArthur, G.A.
|
|
|
28 |
3 |
p. 634-641
|
artikel
|
| 44 |
What is the optimal neoadjuvant treatment for locally advanced oesophageal adenocarcinoma?
|
Mariette, C.
|
|
|
28 |
3 |
p. 447-450
|
artikel
|
Tijdschrift beschrijving